Main Menu

PACE

International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer.

Disease site: Prostate cancerurological cancers

Treatment modality: Radiotherapy and surgery

Status: Open to recruitment

Trial details

PACE is a multicentre, international phase 3 randomised controlled study to assess whether hypofractionated stereotactic body radiotherapy (SBRT) offers therapeutic benefit over prostatectomy or conventional radiotherapy in men with early stage, organ-confined prostate cancer.

Two randomisations (PACE A and PACE B) will run in parallel, sharing a common experimental SBRT arm. A total of 1716 low–intermediate risk patients with a histological confirmation of prostate adenocarcinoma will be recruited.

PACE A will recruit 858 patients considered candidates for surgery, as agreed by both physician and patient. The participants will be randomised to receive either:

  • Laparoscopic prostatectomy; or
  • Prostate SBRT delivered with 36.25 Gy in 5 fractions.

PACE B will recruit 858 patients who are not considered candidates for surgery, or who have declined surgery. These participants will be randomised to receive either:

  • Conventional radiotherapy (investigators choice between 78 Gy in 39 fractions or 62 Gy in 20 fractions); or
  • Prostate SBRT delivered with 36.25 Gy in 5 fractions.

Following completion of trial treatment, all participants will be followed up for 10 years.

Further information

Chief Investigator: Dr Nicholas van As, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial management contact: [email protected]

ISRCTN: 17627211 

Sponsor: The Royal Marsden NHS Foundation Trust

Funding: Accuray

View PACE on the UK Clinical Trials Gateway.

A plain English summary of PACE is available from Cancer Research UK.

Publications and presentations

There have been no presentations or publications to date.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.